KRAS and non-small cell lung carcinoma: In a study comparing clinical outcome after first‐line platinum‐based chemotherapy in KRAS‐mutated NSCLC, significantly improved ORR (P < 0.01) was observed for taxanes in patients with G12V, but not PFS or OS.41